During the year, the first day earnings of 7 new shares exceeded 100000 yuan, and 14 new shares were broken on the first day of listing
Choice data show that this year, three new shares rose more than 1000% on the first day of listing, and 27 new shares rose more than 500% on the first day of listing. Seven new shares made a single signature profit of more than 100000 yuan on the first day of listing. They are Jimi technology, puran shares, Zhongwang software, Haoyuan medicine, power diamond, lightning Weili and Yiqiao Shenzhou. As of December 28, 14 new shares had been broken on the first day of listing, of which Baiji Shenzhou had the largest loss, about 16000 yuan; Chengda biological broke the most, falling 27.27% on the first day of listing.
This text is a result of machine translation.
Related companies：
Briefing Apr 28, 2022 09:59 AM
A new breakthrough in the first-line treatment of advanced esophageal cancer: PD-1 monoclonal antibody baizean ® Global phase 3 clinical trials reached the primary end point
In-depth
Briefing Mar 11, 2022 10:59 AM
· Financials
Baiji China: the tentative list is a normal step and will not affect the listing of the company on NASDAQ
May 02, 2022 07:50 PM
Apr 18, 2022 09:14 PM
Apr 18, 2022 06:30 PM
Apr 11, 2022 08:42 PM
Briefing Feb 25, 2022 08:48 PM
Ministry of agriculture and rural areas: implement the ten-year fishing ban on the Yangtze River in 2022 and promote the conservation of aquatic biological resources
Briefing Feb 15, 2022 06:19 AM
· Automotive
Hillhouse Q4 position: increased holdings of ideal automobile and Xiaopeng automobile sea, and ideal automobile rushed into the top ten
Briefing Jan 31, 2022 10:29 AM
· Healthcare
Hong Kong Pharmaceutical stocks generally rose, with Cinda biology up nearly 6%
Briefing Jan 05, 2022 11:24 AM
· Healthcare
54% off! Pamipali, the first PARP inhibitor approved for the treatment of platinum sensitive and platinum resistant recurrent ovarian cancer, was included in Medicare
Briefing Dec 10, 2021 04:48 PM
· Healthcare
Baiji Shenzhou announced that bevacizumab injection is a biological analogue of pubeshi ® Commercial listing in China
See more
Read next
In-depth
In-depth
Technology
Exclusive Interview with Liu Di, Managing Director of Peakview Capital
May 21, 2022 12:51 PM
In-depth
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.